Coulter Partners secures appointment of Non-Executive Chairman for Agendia

Coulter Partners was delighted to partner with Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, to secure the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.

Patrick’s knowledge and experience in driving rapid growth in technology-led companies is exceptional, and will bolster Agendia’s position in the sector,” said Mark R. Straley, CEO of Agendia. “Agendia is committed to improving the quality of life for cancer patients through molecular diagnostics, one patient at a time, and we are convinced that Patrick’s expertise will help us to achieve this. We warmly welcome him to the role of Chairman and I thank the outstanding team at Coulter Partners for conducting this search on our behalf.”

Agendia’s primary focus is expanding the adoption of clinically useful genetic signatures as an aid to personalizing breast cancer treatment by increasing the geographic reach and reimbursement of these panels, such as its proven MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test. MammaPrint is available globally through many major hospitals to provide physicians and patients access to this essential breast cancer screening test to enable more informed decision-making and more individualized treatment.

“Agendia’s strong vision for transforming breast cancer treatment is inspiring and I look forward to working with the team at this pivotal time for the Company,” said Patrick J. Balthrop.

Patrick J. Balthrop is currently a Director at Oxford Immunotec Global, Personalis, Inc. and Concert Genetics. He is an advisor to Water Street Healthcare Partners and the Founding Principal of Apalachee Ventures, an investment and advisory firm. Patrick previously held positions of CEO, President and Director at Luminex, and President at Fisher Healthcare (then Fisher Scientific).  He has also held a number of positions within Abbott Laboratories, including President of Abbott Vascular and Corporate VP, Worldwide Commercial Operations. Patrick has an MBA from the Kellogg School of Management, Northwestern University and a BS in Biology from Spring Hill College.

Patrick joins Christoph Waer (Korys), Jan Willem Nieuwenhuize (ING Corporate Investments), Erik Leeuwaarden (advisor), Peter Stein (Norgine) and Eric Esveld (Van Herk Groep) on the Board.

About Agendia

Agendia is a privately held, leading molecular diagnostics company that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include MammaPrint®, a 70-Gene Breast Cancer Risk-of-Recurrence test, and BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the field of oncology. For more information, visit